Literature DB >> 18556022

Structural and biochemical characterization of the therapeutic Anabaena variabilis phenylalanine ammonia lyase.

Lin Wang1, Alejandra Gamez, Holly Archer, Enrique E Abola, Christineh N Sarkissian, Paul Fitzpatrick, Dan Wendt, Yanhong Zhang, Michel Vellard, Joshua Bliesath, Sean M Bell, Jeffrey F Lemontt, Charles R Scriver, Raymond C Stevens.   

Abstract

We have recently observed promising success in a mouse model for treating the metabolic disorder phenylketonuria with phenylalanine ammonia lyase (PAL) from Rhodosporidium toruloides and Anabaena variabilis. Both molecules, however, required further optimization in order to overcome problems with protease susceptibility, thermal stability, and aggregation. Previously, we optimized PAL from R. toruloides, and in this case we reduced aggregation of the A. variabilis PAL by mutating two surface cysteine residues (C503 and C565) to serines. Additionally, we report the structural and biochemical characterization of the A. variabilis PAL C503S/C565S double mutant and carefully compare this molecule with the R. toruloides engineered PAL molecule. Unlike previously published PAL structures, significant electron density is observed for the two active-site loops in the A. variabilis C503S/C565S double mutant, yielding a complete view of the active site. Docking studies and N-hydroxysuccinimide-biotin binding studies support a proposed mechanism in which the amino group of the phenylalanine substrate is attacked directly by the 4-methylidene-imidazole-5-one prosthetic group. We propose a helix-to-loop conformational switch in the helices flanking the inner active-site loop that regulates accessibility of the active site. Differences in loop stability among PAL homologs may explain the observed variation in enzyme efficiency, despite the highly conserved structure of the active site. A. variabilis C503S/C565S PAL is shown to be both more thermally stable and more resistant to proteolytic cleavage than R. toruloides PAL. Additional increases in thermal stability and protease resistance upon ligand binding may be due to enhanced interactions among the residues of the active site, possibly locking the active-site structure in place and stabilizing the tetramer. Examination of the A. variabilis C503S/C565S PAL structure, combined with analysis of its physical properties, provides a structural basis for further engineering of residues that could result in a better therapeutic molecule.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18556022      PMCID: PMC2556551          DOI: 10.1016/j.jmb.2008.05.025

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  25 in total

1.  Phosphorylation of phenylalanine ammonia-lyase: evidence for a novel protein kinase and identification of the phosphorylated residue.

Authors:  E G Allwood; D R Davies; C Gerrish; B E Ellis; G P Bolwell
Journal:  FEBS Lett       Date:  1999-08-20       Impact factor: 4.124

2.  Database searching by flexible protein structure alignment.

Authors:  Yuzhen Ye; Adam Godzik
Journal:  Protein Sci       Date:  2004-07       Impact factor: 6.725

3.  Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor.

Authors:  Daumantas Matulis; James K Kranz; F Raymond Salemme; Matthew J Todd
Journal:  Biochemistry       Date:  2005-04-05       Impact factor: 3.162

4.  Strategies to maximize the encapsulation efficiency of phenylalanine ammonia lyase in microcapsules.

Authors:  Ruchi M Shah; Anil P D'mello
Journal:  Int J Pharm       Date:  2008-01-08       Impact factor: 5.875

5.  Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria.

Authors:  Lin Wang; Alejandra Gamez; Christineh N Sarkissian; Mary Straub; Marianne G Patch; Gye Won Han; Steve Striepeke; Paul Fitzpatrick; Charles R Scriver; Raymond C Stevens
Journal:  Mol Genet Metab       Date:  2005-07-11       Impact factor: 4.797

6.  Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria.

Authors:  Alejandra Gámez; Christineh N Sarkissian; Lin Wang; Woomi Kim; Mary Straub; Marianne G Patch; Lin Chen; Steve Striepeke; Paul Fitzpatrick; Jeffrey F Lemontt; Charles O'Neill; Charles R Scriver; Raymond C Stevens
Journal:  Mol Ther       Date:  2005-06       Impact factor: 11.454

7.  A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase.

Authors:  C N Sarkissian; Z Shao; F Blain; R Peevers; H Su; R Heft; T M Chang; C R Scriver
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

8.  Crystal structure of phenylalanine ammonia lyase: multiple helix dipoles implicated in catalysis.

Authors:  Joseph C Calabrese; Douglas B Jordan; Amechand Boodhoo; Sima Sariaslani; Todd Vannelli
Journal:  Biochemistry       Date:  2004-09-14       Impact factor: 3.162

9.  The structure of L-tyrosine 2,3-aminomutase from the C-1027 enediyne antitumor antibiotic biosynthetic pathway.

Authors:  Carl V Christianson; Timothy J Montavon; Steven G Van Lanen; Ben Shen; Steven D Bruner
Journal:  Biochemistry       Date:  2007-05-22       Impact factor: 3.162

10.  Discovery of two cyanobacterial phenylalanine ammonia lyases: kinetic and structural characterization.

Authors:  Michelle C Moffitt; Gordon V Louie; Marianne E Bowman; Janelle Pence; Joseph P Noel; Bradley S Moore
Journal:  Biochemistry       Date:  2007-01-30       Impact factor: 3.162

View more
  22 in total

1.  Computational investigation of the histidine ammonia-lyase reaction: a modified loop conformation and the role of the zinc(II) ion.

Authors:  Amalia-Laura Seff; Sarolta Pilbák; Ioan Silaghi-Dumitrescu; László Poppe
Journal:  J Mol Model       Date:  2010-10-05       Impact factor: 1.810

2.  Optimized condition for enhanced soluble-expression of recombinant mutant anabaena variabilis phenylalanine ammonia lyase.

Authors:  Hossein Zarei Jaliani; Safar Farajnia; Yaghoub Safdari; Seyyed Abolghasem Mohammadi; Abolfazl Barzegar; Saeed Talebi
Journal:  Adv Pharm Bull       Date:  2014-02-07

3.  Clinical therapeutics for phenylketonuria.

Authors:  Jaspreet Singh Kochhar; Sui Yung Chan; Pei Shi Ong; Lifeng Kang
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

4.  Directed evolution of Anabaena variabilis phenylalanine ammonia-lyase (PAL) identifies mutants with enhanced activities.

Authors:  Zachary Js Mays; Karishma Mohan; Vikas D Trivedi; Todd C Chappell; Nikhil U Nair
Journal:  Chem Commun (Camb)       Date:  2020-04-09       Impact factor: 6.222

5.  Probing the active site of MIO-dependent aminomutases, key catalysts in the biosynthesis of beta-amino acids incorporated in secondary metabolites.

Authors:  Heather A Cooke; Steven D Bruner
Journal:  Biopolymers       Date:  2010-09       Impact factor: 2.505

6.  A comprehensive in silico characterization of bacterial signal peptides for the excretory production of Anabaena variabilis phenylalanine ammonia lyase in Escherichia coli.

Authors:  Hajar Owji; Shiva Hemmati
Journal:  3 Biotech       Date:  2018-11-16       Impact factor: 2.406

7.  Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria.

Authors:  Christineh N Sarkissian; Tse Siang Kang; Alejandra Gámez; Charles R Scriver; Raymond C Stevens
Journal:  Mol Genet Metab       Date:  2011-06-29       Impact factor: 4.797

8.  Highly Active and Specific Tyrosine Ammonia-Lyases from Diverse Origins Enable Enhanced Production of Aromatic Compounds in Bacteria and Saccharomyces cerevisiae.

Authors:  Christian Bille Jendresen; Steen Gustav Stahlhut; Mingji Li; Paula Gaspar; Solvej Siedler; Jochen Förster; Jérôme Maury; Irina Borodina; Alex Toftgaard Nielsen
Journal:  Appl Environ Microbiol       Date:  2015-04-24       Impact factor: 4.792

9.  Biochemical and Structural Analysis of Substrate Specificity of a Phenylalanine Ammonia-Lyase.

Authors:  Se-Young Jun; Steven A Sattler; Gabriel S Cortez; Wilfred Vermerris; Scott E Sattler; ChulHee Kang
Journal:  Plant Physiol       Date:  2017-12-01       Impact factor: 8.340

10.  Converting an injectable protein therapeutic into an oral form: phenylalanine ammonia lyase for phenylketonuria.

Authors:  Tse Siang Kang; Lin Wang; Christineh N Sarkissian; Alejandra Gámez; Charles R Scriver; Raymond C Stevens
Journal:  Mol Genet Metab       Date:  2010-01       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.